New developments in the prophylaxis and treatment of graft versus host disease

Bibliography

• SIKORSKI R, PETERS R:Tolerating differences. Science (1999) 285:357–358.
   PubMedGoogle Scholar
• RATANATHARATHORN V, NASH RA, PRZEPIORKA D etal.: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood (1998) 92:2303–2314.
   Google Scholar
• ••This is a large, well-conducted study thatprovides a baseline for GVHD expected with CsA and methotrexate, as well as experience with tacrolimus.
   Google Scholar
• ALLISON AC, EUGUI EM: Mycophenolate mofetil and its mechanisms of action. Immurropharmacology (2000) 47:85–118.
   PubMed Web of Science ®Google Scholar
• LIPSKY JJ: Mycophenolate mofetil. Lancet(1996) 348:1357–1359.
   PubMed Web of Science ®Google Scholar
• DANOVITCH GM: Mycophenolate mofetilin renal transplantation: results from the U.S. randomized trials. Kidney Int. Suppl. (1995) 52:S93–96.
   PubMedGoogle Scholar
• GROTH CG:The European experience with mycophenolate mofetil. European Mycophenolate mofetil Cooperative Study Group. Transplant Proc (1996) 28:30–33.
   PubMedGoogle Scholar
• TOMLANOVICH SJ: Rescue therapy with Mycophenolate mofetil. Mycophenolate mofetil Renal Refractory Rejection Study Group. Transplant Proc (1996) 28:34–36.
   Google Scholar
• Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate mofetil Study Group. Am. Kidney Dis. (1999) 34:296–303.
   PubMed Web of Science ®Google Scholar
• YU C, SEIDEL K, NASH RA etal.: Synergism between Mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood (1998) 91:2581–2587.
   Google Scholar
• VAN LEEUWEN L, GUIFFRE AK, SEWELL WA etal.: Administration of Mycophenolate mofetil in a murine model of acute graft-versus-host disease after bone marrow transplantation. Transplantation (1997) 64:1097–1101.
   Google Scholar
• BORNHAUSER M, SCHULER U, PORKSEN G etal.: Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation (1999) 67:499–504.
   Google Scholar
• MCSWEENEY P, NIEDERWIESER D, SHIZURU J etal.: Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine and Mycophenolate mofetil. Blood (1999) 94:393a.
   Google Scholar
• MOOKERJEE B, ALTOMONTE V, VOGELSANG G: Salvage therapy for refractory chronic graft-versus-host disease with Mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. (1999) 24:517–520.
   PubMed Web of Science ®Google Scholar
• •The combination of MMF and tacrolimus as described in this paper is becoming increasingly used for cGVHD therapy.
   Google Scholar
• BUSCA A, SAROGLIA EM, LANINO E et al.: Mycophenolate mofetil (Mycophenolate motetill as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant (2000) 25:1067–1071.
   PubMed Web of Science ®Google Scholar
• SNYDER SH, SABATINI DM: Immunophilins and the nervous system. Nat. Med. (1995) 1:32–37.
   PubMed Web of Science ®Google Scholar
• LIU J, FARMER JD, Jr., LANE WS etal.: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 66:807–815.
   Google Scholar
• MATSUDA S, SHIBASAKI F, TAKEHANA K et al.: Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep. (2000) 1:428–434.
   PubMed Web of Science ®Google Scholar
• NASH R, ANTIN J, KARANES C etal.: Phase III study comparing tacrolimus (FK506) with cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood (1997) 90.
   Google Scholar
• •This article provides data on the comparison of tacrolimus with CsA in unrelated donor transplants. It provides a useful baseline for the incidence of acute and chronic GVHD with CsA and methotrexate in this setting.
   Google Scholar
• FAY J, WINGARD J, ANTIN J etal.: FK506 (Tacrolimus) monotherapy for prevention of graft- versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood (1996) 8:3514–3519.
   Google Scholar
• NASH RA, PINEIRO LA, STORB R et al.:FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors. Blood (1996) 88:3634–3641.
   PubMed Web of Science ®Google Scholar
• PRZEPIORKA D, IPPOLITI C, KHOURI I et al.: Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood (1996) 88:4383–4389.
   PubMed Web of Science ®Google Scholar
• •Although this suffers from not being a controlled study it provides data on the use of tacrolimus with low dose methotrexate.
   Google Scholar
• PRZEPIORKA D, KHOURI I, IPPOLITI C et al.: Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant (1999) 24:763–768.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clirr. Biochem. (1998) 31:335–340.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN: Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther. Drug Montt. (1995) 17:660–665.
   PubMedGoogle Scholar
• •A useful summary of rapamycin's mechanism of action and comparison with that of CsA and tacrolimus.
   Google Scholar
• WIEDERRECHT GJ, SABERS CJ, BRUNN GJ etal.: Mechanism of action of rapamycin: new insights into the regulation of Gl-phase progression in eukaryotic cells. Frog. Cell Cyde Res. (1995) 1:53–71.
   Google Scholar
• GROTH CG, BACKMAN L, MORALES JM et al.: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation (1999) 67:1036–1042.
   PubMed Web of Science ®Google Scholar
• •Although this study is in renal transplantation, it is good for defining the different side-effect profiles of CsA and rapamycin.
   Google Scholar
• KAHAN BD, PODBIELSKI J, NAPOLI KL et al.: Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation (1998) 66:1040–1046.
   PubMed Web of Science ®Google Scholar
• MCALISTER VC, GAO Z, PELTEKIAN K et al.: Sirolimus-tacrolimus combination immunosuppression [letter]. Lancet (2000) 355:376–377.
   PubMed Web of Science ®Google Scholar
• LI Y, LI XC, ZHENG XX etal.: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. (1999) 5:1298–1302.
   Google Scholar
• •Concerns are raised about the blocking of tolerance induction with combination of traditional immunosuppressives with tolerance induction agents. This interaction is critical for sensible introduction of tolerance induction
   Google Scholar
• CHEN BJ, MORRIS RE, CHAO NJ: Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol. Blood Marrow Transplant (2000) 6:529–536.
   PubMedGoogle Scholar
• POWELL J, FITZHUGH C, KANG E et al.: Rapamycin induces long term marrow chimerism in the absence of long term immunosuppression in mismatched stem cell transplantation: application to sickle cell mice. Blood (2000) 96:580a.
   Google Scholar
• RIGDEN JP, CORNETTA K, SROUR EF etal.: Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation. Bone Marrow Transplant. (1996) 18:913–919.
   PubMedGoogle Scholar
• CHAMPLIN RE, PASS WEG JR, ZHANG MJ etal.: T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood (2000) 95:3996–4003.
   Google Scholar
• ••This retrospective review helps define therole of T-cell depletion and offers the best current comparison between different techniques.
   Google Scholar
• BAURMANN H, REVILLARD JP, BONNEFOY-BERARD N, SCHWERDTFEGER R: Potent effects of ATG used as part of the conditioning in matched unrelated donor transplantation. Blood (1998) 92:1188a.
   Google Scholar
• RUSSELL NH, CULL G, BYRNE JL et al.: Evaluation of non-myeloablative conditioning combining BEAM with in-vivo pre-transplant Campath-1G for allogeneic transplantation in patients with lymphoma. Blood (1999) 94.
   Google Scholar
• HALE G, WALDMANN H: CAMPATH-1 monoclonal antibodies in bone marrow transplantation. j Hematother. (1994) 3:15–31.
   PubMedGoogle Scholar
• KOTTARIDIS PD, MILLIGAN DW, CHOPRA R et al.: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 96:2419–2425.
   PubMed Web of Science ®Google Scholar
• •Campath-1H has dual benefits of having anti-tumour activity with in vivo T-cell depletion. This paper shows the feasibility of combining this with a low toxicity preparative regimen.
   Google Scholar
• BRENNAN DC, FLAVIN K, LOWELL JA etal.: A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation (1999) 67:1011–1018.
   Google Scholar
• •Although a renal transplant study, this is a good comparison of the activity and side-effect profile of these two polyclonal anti-T-cell antibody preparations.
   Google Scholar
• MCCAUL KG, NEVILL TJ, BARNETT MJ et al.: Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. j Hematother. Stem. Cell Res. (2000) 9:367–374.
   PubMedGoogle Scholar
• MATZINGER P: Graft tolerance: a duel of two signals. Nat. Med. (1999) 5:616–617.
   PubMed Web of Science ®Google Scholar
• •This is a short lucid description of the role of CD40 in B- and T-cell immunity
   Google Scholar
• SCHWARTZ RS: The new immunology--the end of immunosuppressive drug therapy? N. Engl. J. Med. (1999) 340:1754–1756.
   PubMed Web of Science ®Google Scholar
• WEINBERG AD, WEGMANN KW, FUNATAKE C, WHITHAM RH: Blocking OX-40/0X-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. j konurrol. (1999) 162:1818–1826.
   Google Scholar
• SAYEGH MET, AKALIN E, HANCOCK WW etal.: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Thl cytokines but spares Th2. _J. Exp. Med. (1995) 181:1869–1874.
   Google Scholar
• UN H, BOLLING SF, LINSLEY PS etal.: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. j Exp. Med (1993) 178:1801–1806.
   Google Scholar
• KIRK AD, HARLAN DM, ARMSTRONG NN etal.: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Li. USA (1997) 94:8789–8794.
   Google Scholar
• GUINAN EC, BOUSSIOTIS VA, NEUBERG D et al.: Transplantation of anergic histoincompatible bone marrow allografts. N Engl. j. Med. (1999) 340:1704–1714.
   PubMed Web of Science ®Google Scholar
• ••This study is a milestone in toleranceinduction for GVHD prophylaxis.
   Google Scholar
• KIRK AD, BURKLY LC, BATTY DS et al.: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. (1999) 5:686–693.
   PubMed Web of Science ®Google Scholar
• ••Many aspects of tolerance induction are defined in this paper including the relative merits of CTLA-4-Ig and anti-CD4OL, and their interaction with standard immunosuppressive agents.
   Google Scholar
• BLAZAR BR, TAYLOR PA, NOELLE RJ, VALLERA DA: CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD4OL:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. j Clin. Invest. (1998) 102:473–482.
   PubMed Web of Science ®Google Scholar
• GOBBURU JV, TENHOOR C, ROGGE MC etal.: Pharmacokineticsidynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. j Phannacol. Exp. Ther. (1998) 286:925–930.
   Google Scholar
• INWALD DE PETERS MJ, WALSHE D et al.: Absence of platelet CD4OL identifies patients with X-linked hyper IgM syndrome. Chit. Exp. Inarnurrol. (2000) 120:499–502.
   Google Scholar
• TAMURA K, NIITANI H, OGURO Met al.: Phase I study of NKT-01. Cancer Chernother. Phannacol. (1995) 36:189–194.
   Google Scholar
• DUTARTRE P, ANNAT J, DERREPAS P:LF 08-0299 induces tolerance after short-term treatment in a fully major histocompatibility mismatched rat cardiac allograft model. Transplant Proc (1995) 27:440–442.
   PubMed Web of Science ®Google Scholar
• ANDOINS C, DE FORNEL D, ANNAT J, DUTARTRE P: Tolerance in a rat cardiac allograft model after short-term treatment with LF 08-0299. Absence of clonal deletion and evidence of CD4+ suppressor cells. Transplantation (1996) 62:1543–1549.
   Google Scholar
• •Tresperimus acts as a tolerance induction agent. This paper shows that this effect is mediated by CD4 cells that shows that tolerance can be adoptively transferred.
   Google Scholar
• KOMESLI S, DUMAS C, DUTARTRE P: Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Int. knnurrophannacol. (1999) 21:349–358.
   Google Scholar
• BERARD JL, VELEZ RU, FREEMAN RB, TSUNODA SM: A review of interleukin-2 receptor antagonists in solid organ transplantation. Phannacotherapy (1999) 19:1127–1137.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, KAHAN BD, RAJAGOPALAN PR et al: Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation (1999) 68:1288–1294.
   PubMed Web of Science ®Google Scholar
• ONRUST SV, WISEMAN LR: Basiliximab. Drugs (1999) 57:207-213; discussion 214.
   Google Scholar
• BELANGER C, ESPEROU-BOURDEAU H, BORDIGONI P etal.: Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant. (1993) 11:293–297.
   Google Scholar
• ANASETTI C, MARTIN PJ, STORB R et al.: Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant. (1991) 7:375–381.
   PubMed Web of Science ®Google Scholar
• BLAISE D, OLIVE D, MICHALLET M et al.: Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet (1995) 345:1144–1146.
   PubMed Web of Science ®Google Scholar
• ANASETTI A, UN A, NADEMANEE A et al.: A phaserandomized, double blind,placebo-controlled multicenter trial of humanized anti-TAC for prevention of acute graft-versus-host disease in recipients of marrow transplants from unrelated donors. Blood (1995) 86:621a.
   Web of Science ®Google Scholar
• •Although only an abstract, this paper summarises early experience with anti-TAC antibodies and is a caveat for extrapolation of results of GVHD treatment to prophylaxis and vice versa.
   Google Scholar
• PRZEPIORKA D, KERNAN NA, IPPOLITI C etal.: Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood (2000) 95:83–89.
   Google Scholar
• •Results of daclizumab for steroid-refractory GVHD are presented in the largest series to date.
   Google Scholar
• PASQUINI R, MOREIRA V, DE MEDEIROS C, BONFIRM C: Basiliximab -a selective interleukin-2 receptor antagonist -as therapy for refractory acute graft- versus-host disease following bone marrow transplantation. Blood (2000) 96:177a.
   Google Scholar
• MARGOLIS J, VOGELSANG G: An old drug for a new disease: pentostatin (Nipent) in acute graft- versus-host disease. Semi]. arca (2000) 27:72–77.
   PubMedGoogle Scholar
• MARGOLIS J, JACOBSOHN D, PHELPS M et al.: Pentostatin: A novel treatment for steroid refractory acute GVHD. Blood (2000) 96:400a.
   Google Scholar
• COURIEL D, HICKS K, IPOLITTI C etal.: Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: an update. Blood (2000) 96:400a.
   Google Scholar
• CHIANG K-Y, MARSHALL C, ABHYANKAR S etal.: Recombinant human soluble tumor necrosis factor receptor fusion protein (Enbrefi as a treatment for chronic graft- versus-host disease following allogeneic bone marrow transplantation. Blood (2000) 96:401a.
   Google Scholar
• GILMAN AL, CHAN KW, MOGUL A et al.: Hydroxychloroquine for the treatment of chronic graft- versus-host disease. Biol. Blood Marrow Transplant (2000) 6:327–334.
   PubMed Web of Science ®Google Scholar